Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Lumen Bioscience

Explore full profile

Discovers, develops and manufactures biologic drugs and vaccine candidates for several prevalent, worldwide diseases

Seattle, United StatesFounded 2017Biotech & Life Sciences
Valuation $250–500M Last recorded · 2025
Headcount 100–500 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Lumen Bioscience and the history behind them.

About Lumen Bioscience

Lumen Bio is a biotechnology startup that is revolutionizing the development and distribution of biologic drugs. Biologic drugs are products that are produced from living organisms or contain components of living organisms. These drugs have immense potential in treating various diseases but have been limited by the lack of scalable technology. Lumen Bio is addressing this gap by leveraging its patented technology to develop these drugs faster, at a lower cost, and with less risk than traditional methods.

The company operates in the biopharmaceutical market, serving a broad range of clients including hospitals, healthcare providers, and patients suffering from diseases such as Inflammatory Bowel Disease (IBD) and metabolic diseases. These are conditions that have been largely neglected by the healthcare industry due to the high costs associated with their treatment.

Lumen Bio's business model is centered around the development and commercialization of biologic drugs. The company makes money by selling these drugs to healthcare providers and hospitals. By reducing the cost and time of development, Lumen Bio is able to offer these drugs at a more affordable price, thereby increasing access for patients who need them.

In addition, Lumen Bio is also addressing other health issues such as gastrointestinal symptoms, which affect a significant number of patients, and diseases that are a leading cause of death worldwide. The company is also developing therapies for mild-to-moderate Crohn's disease and is working to protect travelers and US servicemembers from health risks.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2017
Headquarters
Seattle, United States
Employees
112
Open positions
None listed
Dealroom signal
87.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Algae, Synthetic Biology, Spinout, Alternative Protein, Biotech and Pharma, Blue Economy, Blue Biotechnology, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Oct 2025 $30M $252M Matt Horner · WestRiver Group · Jerry Yang · Jeff Raikes ↗
LATE VCOther financing Sep 2023 $17M $252M Undisclosed ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Lumen Bioscience website traffic

Latest recorded traffic for Lumen Bioscience is 5.4K monthly website visits, up 20% over the last three months. Lumen Bioscience's team grew 8.7% over the past year.

Latest monthly visits5.4K 3-month web change+20% 1-year team growth+8.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

16 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • CARB-X
  • MTEC
  • US Department of War

Series A5 investors entered at this stage

  • Bioeconomy Capital
  • WestRiver Group
  • Columbia Pacific Advisors
  • Jim Roberts
  • Brian Finrow

Series B and later7 investors entered at this stage

  • Matt Horner
  • Jerry Yang
  • Jeff Raikes
  • Adebayo O. Ogunlesi
  • Bill & Melinda Gates Foundation
  • David Siegel
  • Jim Kavanaugh

Other known investors1 additional known investor

  • Fred Hutchinson Cancer Research Center
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Lumen Bioscience on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Lumen Bioscience’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.